LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Arcutis Biotherapeutics Inc

Fermé

SecteurSoins de santé

13.39 -0.67

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.28

Max

13.45

Chiffres clés

By Trading Economics

Revenu

-14M

-25M

Ventes

-5.5M

66M

BPA

-0.2

Marge bénéficiaire

-38.059

Employés

342

EBITDA

-20M

-25M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+56.59% upside

Dividendes

By Dow Jones

Prochains Résultats

13 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-123M

1.7B

Ouverture précédente

14.06

Clôture précédente

13.39

Sentiment de l'Actualité

By Acuity

50%

50%

155 / 381 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 juin 2025, 22:33 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefonica Ecuador for $380 Million

14 juin 2025, 01:24 UTC

Acquisitions, Fusions, Rachats

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 juin 2025, 23:50 UTC

Acquisitions, Fusions, Rachats

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 juin 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 juin 2025, 23:09 UTC

Acquisitions, Fusions, Rachats

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 juin 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 juin 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefonica Ecuador for $380M

13 juin 2025, 22:04 UTC

Market Talk
Acquisitions, Fusions, Rachats

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 juin 2025, 21:42 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 juin 2025, 21:35 UTC

Acquisitions, Fusions, Rachats

Bunge: Outside Date Extended to July 3

13 juin 2025, 21:35 UTC

Acquisitions, Fusions, Rachats

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 juin 2025, 21:34 UTC

Acquisitions, Fusions, Rachats

Bunge Gets Mexico Approval for Viterra Deal

13 juin 2025, 21:32 UTC

Acquisitions, Fusions, Rachats

Bunge Gets China Approval for Viterra Deal

13 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 juin 2025, 20:45 UTC

Acquisitions, Fusions, Rachats

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 juin 2025, 20:34 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 juin 2025, 20:14 UTC

Acquisitions, Fusions, Rachats

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 juin 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 juin 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 juin 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 juin 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 juin 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 juin 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 juin 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 juin 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Comparaison

Variation de prix

Arcutis Biotherapeutics Inc prévision

Objectif de Prix

By TipRanks

56.59% hausse

Prévisions sur 12 Mois

Moyen 21.14 USD  56.59%

Haut 29 USD

Bas 19 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

12.42 / 14.93Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

155 / 381Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.